page-banner

Board of Directors | Acquist Therapeutics

Leadership | Senior Mangement

raymond-p-warrell-icon

Raymond P. Warrell, Jr. M.D.

Raymond P. Warrell, M.D.

Founder, Chief Executive Officer, and Member of the Board

Founder, Chief Executive Officer, and Member of the Board

Inventor of the Acquist drug prototype, Ray has more than 25 years of achievement in scientific research, clinical development, finance, operations, regulatory affairs, and senior management experience in the pharmaceutical, diagnostic, and biotechnology sectors.

Ray was the lead inventor of two earlier drugs, drafted their INDs, secured their designations as “Orphan Drugs”, and designed and led the Phase 1-3 clinical trials that were pivotal for FDA approval. These drugs were acquired by Fujisawa (Astellas Inc.) and Cell Therapeutics Inc. In recognition of this work, he received FDA’s Public Health Service Award for “Exceptional Achievement in Orphan Drug Development”. Ray has received more than 25 patents for discrete inventions and more than 100 world-wide issued filings. He has published more than 110 scientific papers, primarily in oncology, hematology, arthritis, and metabolism.

Prior to founding Acquist, Ray was Chief Executive Officer and Chairman of Genta Inc. (GNTA), a biotechnology company focused on mRNA regulation of cancer cell apoptosis. Previously, he was Associate Physician-in-Chief and Tenured Member at Memorial Sloan-Kettering Cancer Center in New York. He was also Professor of Medicine at the Weill Cornell University Medical College. He received a B.S degree in Chemistry from Emory University, a M.D. from the Medical College of Georgia, and a M.B.A. from Columbia University.

Raymond P. Warrell, M.D.

Inventor of the Acquist drug prototype, Ray has more than 25 years of achievement in scientific research, clinical development, finance, operations, regulatory and legal affairs, and senior executive business management in the pharmaceutical, diagnostic, and biotechnology sectors.

Ray was the lead inventor of two earlier drugs, drafted their INDs, secured their designations as “Orphan Drugs”, and designed and led the Phase 1-3 clinical trials that were pivotal for FDA approval. These drugs were acquired by Fujisawa (Astellas) and Cell Therapeutics Inc. For this work, he received FDA’s Public Health Service Award for “Exceptional Achievement in Orphan Drug Development”.

Ray was Chief Executive Officer and Chairman of Genta Incorporated (Nasdaq: GNTA), a biotechnology company focused on mRNA regulation of cancer cell apoptosis. Previously, he was an Associate Physician-in-Chief and Member at Memorial Sloan-Kettering Cancer Center in New York, and Professor of Medicine at the Weill Cornell University Medical College. He received a B.S (Chemistry) from Emory University, a M.D. from the Medical College of Georgia, and a M.B.A. from Columbia University.

tom-haverty-icon

Thomas P. Haverty, MD

Director

Dr. Haverty has more than 30 years of pharmaceutical and biotechnology experience. He has led teams in clinical research and operations for numerous drug classes and medical indications. With successful development records, these teams achieved regulatory approvals of more than 20 leading drugs.

He is currently interim Chief Medical Officer (CMO) at Eloxx Pharmaceuticals, where he oversees clinical studies of eukaryotic read-through agents in rare hereditary diseases. Dr. Haverty previously held leadership roles at Immusan T, Merck Research Labs, Schering-Plough Research Institute, and Johnson & Johnson’s Pharmaceutical Research Institutes.

Dr. Haverty received a joint B.S. degree in Chemistry and Biology at Stanford University and an M.D. at the University of California, San Diego. He trained as a clinical fellow in both Medicine and Nephrology, and became Attending Physician at the Hospital of the University of Pennsylvania. Subsequently, he was appointed Assistant Professor at the University of Pennsylvania and Associate Professor of Medicine at the University of Alabama, Birmingham.

john-redman-icon

John R. Redman, MD

Director

Dr. John Redman has more than 30 years of experience in the biopharmaceutical industry, with leadership roles in clinical development, medical affairs, and regulatory oversight and strategy. He has supervised clinical programs that led to regulatory approvals of more than 15 new drugs.

Dr. Redman is currently Chief Executive Officer of Proteus Ventures LLC. Most recently, he worked as a clinical consultant for Takeda Pharmaceuticals, Jounce Therapeutics, Sanofi Genzyme, and Curis. Previously, Dr. Redman held leadership development roles at ICON, Incyte, Celator, and Wyeth Ayerst (now Pfizer).

Dr. Redman received an A.B. at Bowdoin College, an MD at the University of Vermont College of Medicine, and an MBA at the Wharton School of the University of Pennsylvania. He completed his medical residency at the Cornell Cooperating Hospitals and his hematology-oncology fellowship at Memorial Sloan-Kettering Cancer Center, New York. Subsequently, he was Assistant Professor of Medicine at the MD Anderson Cancer Center, Houston, TX.

Copyright © 2020 Acquist Theraputics, Inc.® 

Website by CreatedByEric